Abstract
4-Benzyl-1-[4-(1H-imidazol-4-yl)but-3-ynyl]piperidine (8) has been identified as a potent antagonist of the NR1A/2B subtype of the NMDA receptor. When dosed orally, this compound potentiates the effects of L-DOPA in the 6-hydroxydopamine-lesioned rat, a model of Parkinson's disease.
MeSH terms
-
Animals
-
Disease Models, Animal
-
Imidazoles / chemical synthesis*
-
Imidazoles / pharmacology*
-
Levodopa / agonists
-
Levodopa / pharmacology
-
Ligands
-
Molecular Structure
-
Oxidopamine
-
Parkinsonian Disorders / metabolism
-
Piperidines / chemical synthesis*
-
Piperidines / pharmacology
-
Pyrazoles / chemical synthesis
-
Pyrazoles / pharmacology*
-
Pyrroles / chemical synthesis
-
Pyrroles / pharmacology*
-
Rats
-
Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
Substances
-
4-benzyl-1-(4-(1H-imidazol-4-yl)but-3-ynyl)piperidine
-
Imidazoles
-
Ligands
-
NR2B NMDA receptor
-
Piperidines
-
Pyrazoles
-
Pyrroles
-
Receptors, N-Methyl-D-Aspartate
-
Levodopa
-
Oxidopamine